Preliminary results in tracheal replacement using stented aortic matrices for primary extensive tracheal cancer.

Abstract

Recent studies have demonstrated the feasibility and favorable long-term results of tracheobronchial replacement using stented cryopreserved aortic allografts. We propose to investigate the outcomes of this emerging technique in the subgroup of patients with extensive tracheal cancer. This study was based on 13 patients with primary extensive tracheal cancer extracted from the prospective registry TRITON-01 (ClinicalTrials.gov Identifier: NCT04263129), which included 40 patients in total. We analyzed early and late outcomes in this subset of patients. From March 2019 to September 2022, 13 patients were included in the study. There were 9 female and 4 male patients, with a mean age of 53.9years [36-71 years]. They had tracheal replacement for extended adenoid cystic carcinoma (n=11), squamous cell carcinoma (n=1), and mucoepidermoid carcinoma (n=1). A venovenous extracorporeal membrane oxygenation was used in the 6 last cases. The mean length of resection was 81 mm [50-120 mm]. There was no 30-day postoperative mortality. A complete resection (R0) was achieved in 11 patients. The main late complications consisted of tracheal granulomas related to the stent and requiring repeated bronchoscopies (n=9), pneumonia (n=3), airway infection (n=1), bronchoesophageal fistula (n=1), mechanical stent obstruction requiring change (n=2), and mediastinitis treated by antibiotics, drainage, and omentoplasty (n=1). With a maximal follow-up of 3years and 7months, cancer recurrence was observed in 2 patients. All patients were alive at last follow-up except 2 (84.6%). Airway replacement using stented CAA represents a feasible and promising solution for extensive tracheal cancer.